
Please try another search
By Sam Boughedda
Investing.com — Medical device and health care company Abbott Laboratories (NYSE:ABT) saw its shares rise over 2% following a price target raise and bullish comments from Raymond James analyst Jayson Bedford.
The analyst raised Abbott's price target to $150 from $134, while maintaining a Outperform rating. Bedford cited the company's portfolio as being a key reason in his price target raise, stating it is "durable" enough to withstand increasing Covid-related pressures.
"We continue to favor ABT’s positioning as its portfolio is durable enough (CV-testing, Nutrition, EPD) to withstand increasing CV-pressures near-term, but also benefit (in Med Devices) after we work our way through yet another CV-wave. ABT’s diversified portfolio also addresses fast-growing end markets (Diabetes, Structural Heart), with a unique geographic tilt towards Emerging Markets (~35-40% of sales)," Bedford told investors in a research note.
He later said the company's above average growth, and upward estimates supported the firm is maintaining its Outperform rating.
"Valuation is an uncomfortable factor, but ABT remains one of the fastest growing mega-cap (>$200B) healthcare companies, and we believe investors will continue to pay up for sustainable growth stories."
Analysts at RBC Capital and Citi also agree with Bedford. Earlier in December, RBC started Abbott with an Outperform rating and $146 price target, commenting on its "strong base business," while Citi increased its price target on the shares to $154 from $141.
By Bianca Flowers and Joseph White BONDURANT, Iowa (Reuters) - Deere (NYSE:DE) & Co has sold its tractors and other equipment to farmers for decades, but the world's largest...
By Senad Karaahmetovic Shares of NVIDIA (NASDAQ:NVDA) are down more than 5.5% in premarket trading Thursday after the tech giant issued downbeat revenue guidance. NVIDIA reported...
By Huw Jones LONDON (Reuters) -Britain's twin-track company listing regime could be simplified into a single entry point to the London Stock Exchange to attract more startups, the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.